Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of Xinchuotuo in patients with primary hypertension
CTR20262565Phase 4Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sacubitril + allisartan calcium in essential hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Jul 2026; status: active.
02
Drugs
sacubitril + allisartan calcium
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20262565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262565.